Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE 327 Against All Six ESKAPE Pathogens
- More than 99.9% effective against full suite of ESKAPE pathogens, within hours of exposure to RECCE 327 (R327) in independent bacterial efficacy studies
- R327 remains effective against hypermutated ESKAPE superbugs, including multi-drug resistant (MDR) forms, a current market challenge of all existing antibiotics
On-track to be the only company developing an efficacious anti-infective against ESKAPE pathogens globally
SYDNEY, Australia, May 04, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, is pleased to announce RECCE 327 (R327) has demonstrated bactericidal activity against all six antibiotic resistant ESKAPE pathogens, including drug resistant mutations (superbugs) as well as two additional World Health Organization (WHO) priority pathogens list.
“We are encouraged by the data from this study and will continue to explore the potential of RECCE 327 to treat hospital-acquired infections,” said Recce Pharmaceuticals CEO James Graham. “Antimicrobial resistance is one of the most urgent threats to global public health with the suite of ESKAPE pathogens posing a significant threat due to their virulence and rapid development of drug-resistance. Additionally, with R327 effective against two more priority pathogens listed by the WHO, we believe this reinforces the potential of R327 to treat some of the greatest threats to human health.”
These antibiotic resistant bacteria acronymically dubbed 'ESKAPE' due to their propensity of 'escaping' the biocidal action of antibiotics, are collectively responsible for over 720,000 hospital acquired (nosocomial) infections in the United States alone each year.1 The ESKAPE pathogens include both Gram-positive and Gram-negative bacteria; Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.
The study was conducted by an independent contract research organization to assess the in-vitro efficacy of R327 against all ESKAPE pathogen bacterial strains. R327 is a broad-spectrum synthetic anti-infective that has potential to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens.
Graphics accompanying this announcement are available at